Compositions, methods and devices for forming implants from injected liquids
A method of forming an implant in the tissue can include: providing an injectable composition having a neat liquid carrier, wherein the neat liquid carrier is substantially liquid at room temperature and/or about body temperature; and injecting the neat liquid solution into the tissue at the rate of 10-12000 injections per minute and/or at an amount of 1.0E-02 ml to 1.0E-16 ml per needle per injection. The neat liquid carrier can be polymeric or non-polymeric. The neat liquid carrier can be biodegradable. The neat liquid carrier can include a viscosity-modifying agent. The injecting can form an implant with area greater than or equal to 5 mm 2 . The neat liquid carrier can be injected at a depth of 10 microns to 5 mm. The neat liquid solution can include a drug or other agent.
1. A method of forming an implant in the tissue, the method comprising:
providing an injectable composition having a neat liquid carrier, wherein the neat liquid carrier is substantially liquid at room temperature and/or about body temperature; and
injecting the neat liquid solution into the tissue at the rate of 10-12000 injections per minute and/or at an amount of 1.0E-02 ml to 1.0E-16 ml per needle per injection.
2. The method according to claim 1 , wherein the neat liquid carrier is polymeric or non-polymeric.
3. The method according to claim 1 , wherein the neat liquid carrier is biodegradable.
4. The method according to claim 3 , wherein the biodegradable neat liquid carrier is selected from a group consisting of: polymers, dendramers, copolymers or oligomers of glycolide, dl-lactide, d-lactide, l-lactide, caprolactone, dioxanone and trimethylene carbonate; degradable polyurethanes; polyamides; polyesters; polypeptides; polyhydroxyacids;
polyorthocarbonates; polylactic acid; polyglycolic acid; polyanhydrides; and polylactones; a copolymer of polyethylene glycol and polylactone; and a copolymer of PEO-PPO-PEO and polylactone.
5. The method according to claim 2 , wherein the non-polymeric neat liquid carrier is selected from a group consisting of: sucrose acetate isobutyrate; vitamin E and its derivatives; fatty acids; oleic acids and its derivatives; fatty alcohols; liquid non-ionic surfactants; polysorbate, Tween.40 or Tween 80.
6. The method according to claim 1 , wherein the neat liquid carrier comprises a viscosity-modifying agent.
7. The method according to claim 6 , wherein the viscosity-modifying agent is a biocompatible organic solvent.
8. The method according to claim 6 , wherein the viscosity-modifying agent is selected from the group consisting of dimethyl sulfoxide, n-methyl pyrrolidinone, ethanol, glycerol, polyethylene glycol, and acetone.
9. The method according to claim 6 , wherein the viscosity-modifying agent is added in 1 to 99 percent of the neat liquid carrier.
10. The method according to claim 1 , comprising injecting the composition to form an implant having an area greater than or equal to 5 mm 2 .
11. The method according to claim 1 , wherein the neat liquid carrier includes a visualization agent.
12. The method according to claim 11 , wherein the visualization agent is a coloring composition, a fluorescent composition, a radio opaque contrast agent, or an NMR contrast agent.
13. The method of claim 1 , comprising injecting the neat liquid carrier at a depth of 10 microns to 5 mm.
14. The method of claim 1 , wherein the neat liquid solution comprises a drug.
15. The method of claim 14 , wherein the drug is dissolved, suspended or emulsified in the neat liquid carrier before the injecting.
16. The method of claim 15 , wherein the drug concentration in the neat liquid carrier is 0.1 to 40 percent.
17. The method of claim 14 , wherein the drug is selected from the group consisting of antiinfectives, antibiotics, antiviral agents, antifungal agents, antibacterial agents, antipruritics, anticancer agents, antipsychotics, cholesterol- or lipid-reducing agents, cell cycle inhibitors, anticancer agents, antiparkinsonism drugs, HMG-CoA inhibitors, antirestenosis agents, antiinflammatory agents, antiasthmatic agents, anthelmintics, immunosuppressives, muscle relaxants, antidiuretic agents, vasodilators, nitric oxide, nitric oxide-releasing compounds, beta-blockers, hormones, antidepressants, decongestants, calcium channel blockers, growth factors, bone growth factors, bone morphogenic proteins, wound healing agents, analgesics, analgesic combinations, local anesthetic agents, antihistamines, sedatives, angiogenesis-promoting agents, angiogenesis-inhibiting agents, and tranquilizers.
18. The method of claim 1 , wherein the tissue is a live tissue.
19. The method of claim 1 , wherein the tissue is a bioprosthesis tissue.
20. A method of forming an implant in the tissue, the method comprising:
providing an injectable composition having a neat liquid carrier and an agent, wherein the neat liquid carrier is substantially liquid at room temperature and/or about body temperature; and
injecting the neat liquid solution into the tissue at the rate of 10-12000 injections per minute and/or at an amount of 1.0E-02 ml to 1.0E-16 ml per needle per injection.